Arformoterol

Arformoterol
Clinical data
Trade names Brovana
AHFS/Drugs.com Monograph
MedlinePlus a602023
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration
    Inhalation solution for nebuliser
    ATC code
    • none
    Legal status
    Legal status
    Pharmacokinetic data
    Protein binding 52–65%
    Elimination half-life 26 hours
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    ChEBI
    ChEMBL
    Chemical and physical data
    Formula C19H24N2O4
    Molar mass 344.405 g/mol
     ☒N☑Y (what is this?)  (verify)

    Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]

    It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

    References

    1. "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.